Arizona State University enters next $9 million phase of radiation diagnostic test project
The multi-institutional development will utilize $9 million to produce a test that can rapidly diagnose an individual's level of radiation absorption after a nuclear or radiological event.
The Biodesign Institute will collaborate with Life Sciences Solutions at Thermo Fisher Scientific on the project.
"We are proud to be moving forward in this ambitious, challenging project that combines ASU's considerable research strengths in biomarkers with Thermo Fisher's expertise in the productcommercialization process," Joshua LaBaer, the director of the Biodesign Institute's Virginia G. Piper Center for Personalized Diagnostics, said. "Our research team's ultimate goal is to translate our discoveries for development of an automated high-throughput system for radiation biodosimetry that is capable of processing a high volume of blood samples per day for gene expression analysis."
There is currently no FDA-cleared system that can quickly measure the radiation absorbed by an individual. The Biodesign Institute and Thermo Fisher will eventually submit their plans for a real-time quantitative PCR-based assay system for FDA approval, with Thermo Fisher taking the lead on the submission process.
The diagnostic development project is part of a potential $31.2 million in funds authorized by the federal Biomedical Advanced Research and Development Authority.